Brief: Inhibikase Therapeutics Announces Publication Highlighting Results From Its Phase 1 Studies
29/01/2024 14:12
Jan 29 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES PUBLICATION HIGHLIGHTING
RESULTS FROM ITS PHASE 1 STUDIES WITH RISVODETINIB
* INHIBIKASE THERAPEUTICS INC - DATA DEMONSTRATED THAT
RISVODETINIB WAS WELL TOLERATED UP TO 7 DAYS OF DAILY DOSING
Source text for Eikon: ID:nGNX1k7NWL
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary